Best ASX stock Pharmaust for the next 10 years, page-10

Just to clarify, it is not the case that the survival rate chance is 1 in a 1,000.

In its announcement PAA is dealing with the formalities of null hypothesis testing in statistical analysis.

The null hypothesis is that monepantel did not lengthen survival rates, when compared with the information we already have about untreated death rates for MND.

It turns out that PAA's result after treatment, when comparing monepantel results with general death rates for MND, is that there is a less than 1 in 1,000 chance that PAA's survival rate would have been achieved in an untreated sample.

So the substantive conclusion is that monepantel has had a beneficial effect on the sample of MND sufferers that PAA dosed with monepantel.